Cargando…

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) of osimertinib in patients with epidermal growth factor receptor (EGFR)‐mutated non–small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Yutaka, Makihara, Reiko, Hase, Tetsunari, Hashimoto, Naozumi, Naito, Tomoyuki, Tsubata, Yukari, Okuno, Takae, Takahashi, Toshiaki, Kobayashi, Haruki, Shinno, Yuki, Zenke, Yoshitaka, Ikeda, Takaya, Hosomi, Yukio, Watanabe, Kageaki, Kitazono, Satoru, Sakiyama, Naomi, Makino, Yoshinori, Yamamoto, Noboru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154887/ https://www.ncbi.nlm.nih.gov/pubmed/36704833 http://dx.doi.org/10.1111/cas.15736

Ejemplares similares

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration
por: Hotta, Takamasa, et al.
Publicado: (2021)

Intracranial complete response for non‐small‐cell lung cancer patient with negative PD‐L1 expression of the lung using nivolumab
por: Kitadai, Rui, et al.
Publicado: (2021)

Use of saline to evaluate a cavity due to Mycobacterium kansasii infection during ultrathin bronchoscopy and endobronchial ultrasonography
por: Hamaguchi, Megumi, et al.
Publicado: (2021)

Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study
por: Watanabe, Kageaki, et al.
Publicado: (2022)

Mixed response to osimertinib and the beneficial effects of additional local therapy
por: Shinno, Yuki, et al.
Publicado: (2019)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

An endobronchial hamartoma observed using narrow band imaging under saline injection: A case report
por: Kobayashi, Misato, et al.
Publicado: (2022)

Ultra-magnifying Imaging of Thoracoscopic Biopsy Specimens Using Ex vivo Endocytoscopy in Three Patients with Mesothelioma
por: Shiratsuki, Yohei, et al.
Publicado: (2022)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin
por: Watanabe, Kageaki, et al.
Publicado: (2020)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations
por: Uehara, Yuji, et al.
Publicado: (2022)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
por: Kobayashi, Takayuki, et al.
Publicado: (2023)

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration
por: Nakashima, Kazuhisa, et al.
Publicado: (2023)

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer
por: Matsuzawa, Reiko, et al.
Publicado: (2021)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Acute Exacerbation of Tracheal Obstruction and Severe Respiratory Failure after a Single Dose of 2-Gy Irradiation for Squamous Cell Lung Carcinoma: A Case Report
por: Kawakado, Keita, et al.
Publicado: (2022)

Usefulness of endocytoscopy in evaluating transbronchial biopsy specimens
por: Okuno, Takae, et al.
Publicado: (2022)

Comparison of Ultra-Magnifying Endocytoscopic and Hematoxylin-Eosin-Stained Images of Lung Specimens
por: Kobayashi, Misato, et al.
Publicado: (2023)

Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer
por: Shimizu, Takahiro, et al.
Publicado: (2020)

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
por: Kato, Yasuhiro, et al.
Publicado: (2019)

Varicella-zoster Virus Related Pulmonary Granulomas in Which Varicella-zoster Virus DNA Was Demonstrated in a Thoracoscopic Lung Biopsy Specimen
por: Isobe, Takeshi, et al.
Publicado: (2019)

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center
por: Okuma, Yusuke, et al.
Publicado: (2014)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report
por: Fukuda, Yuko, et al.
Publicado: (2022)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Prospective clinical trial evaluating vulnerability and chemotherapy risk using geriatric assessment tools in older patients with lung cancer
por: Tsubata, Yukari, et al.
Publicado: (2019)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma
por: Okuno, Yumiko, et al.
Publicado: (2011)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vjo4agi80uhbdcnnnak8461s6e